Theravance Biopharma Reports Declining R&D Costs Post CYPRESS Enrollment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 11 2026
0mins
Should l Buy TBPH?
Source: Newsfilter
- Investor Losses: Following the disclosure of the Phase 3 CYPRESS trial failure on March 3, 2026, Theravance Biopharma shareholders experienced approximately a 26% loss in their investments, indicating significant financial pressure that may affect future fundraising capabilities.
- R&D Spending: The company reported $22 million in operating expenses during the CYPRESS trial enrollment, highlighting substantial cash burn on a single high-risk program, which raises concerns about the company's financial health among investors.
- Cost Decline Claims: Although Theravance framed R&D costs as declining post-enrollment, the actual spending underscores a reliance on a failed trial, potentially impacting future R&D strategies and investor confidence.
- Legal Consultation Information: TBPH investors who suffered losses are encouraged to contact Joseph E. Levi, Esq. for more information, which may lead to potential class action lawsuits, further affecting the company's reputation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TBPH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TBPH
Wall Street analysts forecast TBPH stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 14.010
Low
13.00
Averages
28.40
High
42.00
Current: 14.010
Low
13.00
Averages
28.40
High
42.00
About TBPH
Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development and commercialization of medicines for the specialty respiratory and neurologic diseases. The Company operates through a single segment, namely, development and commercialization of human therapeutics. Its product, YUPELRI (revefenacin) inhalation solution, is a nebulized long-acting muscarinic antagonist used for the treatment of patients with chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in the lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Its Ampreloxetine, is a late-stage investigational norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Multiple System Atrophy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Theravance Biopharma Reports Q4 2025 Financial Results
- Net Income Performance: Theravance Biopharma reported a net income of $61.0 million for Q4 2025, indicating stable profitability in the market despite challenges in drug development.
- Revenue Situation: The total revenue for the quarter was $45.9 million, reflecting the company's ongoing efforts in product sales and marketing, although the overall market environment remains uncertain.
- Cash Reserves: As of December 31, 2025, the company had cash, cash equivalents, and marketable securities totaling $326.5 million, providing robust financial support for future R&D and operations.
- R&D Challenges: Theravance faced setbacks in late-stage clinical trials, leading to the termination of its rare disease drug development, a decision that may negatively impact future revenue growth and market confidence.
See More
Theravance Biopharma Reports Record Q4 2025 Results and Strategic Restructuring
- Record Financial Performance: Theravance Biopharma achieved a record non-GAAP profitability in Q4 2025, with YUPELRI® brand profitability hitting an all-time high and $75 million in sales-based milestones, underscoring the company's strong performance and financial stability in the COPD treatment market.
- Organizational Restructuring: The company is implementing a restructuring plan expected to reduce operating expenses by approximately 60% from 2025's $111.1 million, with projected annual cash flow of $60 to $70 million by Q3 2026, enhancing its competitive position in the market.
- Strategic Review Committee Formation: Theravance's Board has established a Strategic Review Committee to evaluate various strategic alternatives, including a potential sale of the company, aimed at maximizing shareholder value, reflecting the company's commitment to future growth.
- Workforce Reduction Impact: The restructuring will affect about 50% of the workforce, completely winding down the R&D department and reducing G&A staff, with expected one-time severance costs of $5 to $7 million, indicating a significant shift in resource allocation.
See More
Theravance Biopharma Restructuring Plan and Financial Performance
- Organizational Restructuring: Theravance Biopharma is implementing an organizational restructuring expected to reduce operating expenses by approximately 60% by Q3 2026, generating annual cash flow of $60 to $70 million, thereby enhancing financial flexibility.
- YUPELRI® Sales Growth: In 2025, YUPELRI® achieved net sales of $266.6 million, a 12% year-over-year increase, triggering a $25 million milestone payment, demonstrating strong performance in the chronic obstructive pulmonary disease market.
- TRELEGY Milestone Income: GSK reported global net sales of approximately $3.9 billion for TRELEGY in 2025, a 13% increase, resulting in a $50 million milestone income, with potential for an additional $100 million milestone payment in 2026, further enhancing revenue prospects.
- Improved Financial Position: Theravance expects to have approximately $400 million in cash and no debt by the end of Q1 2026, indicating robust financial management and providing ample funding for future strategic investments.
See More
Theravance Biopharma Reaffirms Financial Guidance Amid Trial Failure Risks
- Stock Price Collapse: Theravance Biopharma's shares plummeted approximately 26% on March 3, 2026, reflecting a strong market reaction to the failure of its CYPRESS Phase 3 trial, severely undermining investor confidence.
- Reaffirmed Financial Guidance: Prior to the stock drop, management reiterated a $75 million near-term milestone target during the Q3 2025 earnings call, yet failed to disclose the potential risks associated with the CYPRESS trial's failure, indicating a significant oversight in risk assessment.
- Accelerated Strategic Review: Following the CYPRESS trial's inability to meet its primary endpoint, Theravance announced an accelerated strategic review and the termination of the ampreloxetine program, which may lead to restructuring costs and a fundamental reassessment of development-stage spending, impacting the company's future trajectory.
- Investor Losses: The lack of adequate disclosure regarding the risks of the CYPRESS trial has resulted in significant losses for investors, leading to increased pressure for legal consultations and potential class-action lawsuits, which could further damage the company's reputation and shareholder trust.
See More
Theravance Biopharma Reaffirms Financial Guidance Amid Trial Failure
- Stock Price Collapse: Theravance Biopharma's shares plummeted approximately 26% on March 3, 2026, reflecting a strong market reaction to the failure of its CYPRESS Phase 3 trial, which severely undermined investor confidence.
- Reaffirmed Financial Guidance: In the quarters leading up to the drop, management reaffirmed financial guidance, including $75 million in near-term milestone targets, without quantifying the potential risks of a CYPRESS trial failure, which may lead to diminished investor trust in the company's future.
- Accelerated Strategic Review: Following the CYPRESS trial's failure to meet its primary endpoint, Theravance announced an accelerated strategic review and the termination of the ampreloxetine program, a decision that could incur restructuring costs and necessitate a fundamental reassessment of development-stage spending, further impacting the company's financial outlook.
- Investor Losses: The lack of adequate disclosure regarding the risks associated with the CYPRESS trial has left many investors facing losses, significantly increasing the demand for legal consultation and claims, which may lead to subsequent litigation.
See More
Theravance Biopharma Reports Declining R&D Costs Post CYPRESS Enrollment
- Investor Losses: Following the disclosure of the Phase 3 CYPRESS trial failure on March 3, 2026, Theravance Biopharma shareholders experienced approximately a 26% loss in their investments, indicating significant financial pressure that may affect future fundraising capabilities.
- R&D Spending: The company reported $22 million in operating expenses during the CYPRESS trial enrollment, highlighting substantial cash burn on a single high-risk program, which raises concerns about the company's financial health among investors.
- Cost Decline Claims: Although Theravance framed R&D costs as declining post-enrollment, the actual spending underscores a reliance on a failed trial, potentially impacting future R&D strategies and investor confidence.
- Legal Consultation Information: TBPH investors who suffered losses are encouraged to contact Joseph E. Levi, Esq. for more information, which may lead to potential class action lawsuits, further affecting the company's reputation.
See More
Theravance Biopharma Reports Q4 2025 Financial Results
- Net Income Performance: Theravance Biopharma reported a net income of $61.0 million for Q4 2025, indicating stable profitability in the market despite challenges in drug development.
- Revenue Situation: The total revenue for the quarter was $45.9 million, reflecting the company's ongoing efforts in product sales and marketing, although the overall market environment remains uncertain.
- Cash Reserves: As of December 31, 2025, the company had cash, cash equivalents, and marketable securities totaling $326.5 million, providing robust financial support for future R&D and operations.
- R&D Challenges: Theravance faced setbacks in late-stage clinical trials, leading to the termination of its rare disease drug development, a decision that may negatively impact future revenue growth and market confidence.
See More
Theravance Biopharma Reports Record Q4 2025 Results and Strategic Restructuring
- Record Financial Performance: Theravance Biopharma achieved a record non-GAAP profitability in Q4 2025, with YUPELRI® brand profitability hitting an all-time high and $75 million in sales-based milestones, underscoring the company's strong performance and financial stability in the COPD treatment market.
- Organizational Restructuring: The company is implementing a restructuring plan expected to reduce operating expenses by approximately 60% from 2025's $111.1 million, with projected annual cash flow of $60 to $70 million by Q3 2026, enhancing its competitive position in the market.
- Strategic Review Committee Formation: Theravance's Board has established a Strategic Review Committee to evaluate various strategic alternatives, including a potential sale of the company, aimed at maximizing shareholder value, reflecting the company's commitment to future growth.
- Workforce Reduction Impact: The restructuring will affect about 50% of the workforce, completely winding down the R&D department and reducing G&A staff, with expected one-time severance costs of $5 to $7 million, indicating a significant shift in resource allocation.
See More
Theravance Biopharma Restructuring Plan and Financial Performance
- Organizational Restructuring: Theravance Biopharma is implementing an organizational restructuring expected to reduce operating expenses by approximately 60% by Q3 2026, generating annual cash flow of $60 to $70 million, thereby enhancing financial flexibility.
- YUPELRI® Sales Growth: In 2025, YUPELRI® achieved net sales of $266.6 million, a 12% year-over-year increase, triggering a $25 million milestone payment, demonstrating strong performance in the chronic obstructive pulmonary disease market.
- TRELEGY Milestone Income: GSK reported global net sales of approximately $3.9 billion for TRELEGY in 2025, a 13% increase, resulting in a $50 million milestone income, with potential for an additional $100 million milestone payment in 2026, further enhancing revenue prospects.
- Improved Financial Position: Theravance expects to have approximately $400 million in cash and no debt by the end of Q1 2026, indicating robust financial management and providing ample funding for future strategic investments.
See More
Theravance Biopharma Reaffirms Financial Guidance Amid Trial Failure Risks
- Stock Price Collapse: Theravance Biopharma's shares plummeted approximately 26% on March 3, 2026, reflecting a strong market reaction to the failure of its CYPRESS Phase 3 trial, severely undermining investor confidence.
- Reaffirmed Financial Guidance: Prior to the stock drop, management reiterated a $75 million near-term milestone target during the Q3 2025 earnings call, yet failed to disclose the potential risks associated with the CYPRESS trial's failure, indicating a significant oversight in risk assessment.
- Accelerated Strategic Review: Following the CYPRESS trial's inability to meet its primary endpoint, Theravance announced an accelerated strategic review and the termination of the ampreloxetine program, which may lead to restructuring costs and a fundamental reassessment of development-stage spending, impacting the company's future trajectory.
- Investor Losses: The lack of adequate disclosure regarding the risks of the CYPRESS trial has resulted in significant losses for investors, leading to increased pressure for legal consultations and potential class-action lawsuits, which could further damage the company's reputation and shareholder trust.
See More
Theravance Biopharma Reaffirms Financial Guidance Amid Trial Failure
- Stock Price Collapse: Theravance Biopharma's shares plummeted approximately 26% on March 3, 2026, reflecting a strong market reaction to the failure of its CYPRESS Phase 3 trial, which severely undermined investor confidence.
- Reaffirmed Financial Guidance: In the quarters leading up to the drop, management reaffirmed financial guidance, including $75 million in near-term milestone targets, without quantifying the potential risks of a CYPRESS trial failure, which may lead to diminished investor trust in the company's future.
- Accelerated Strategic Review: Following the CYPRESS trial's failure to meet its primary endpoint, Theravance announced an accelerated strategic review and the termination of the ampreloxetine program, a decision that could incur restructuring costs and necessitate a fundamental reassessment of development-stage spending, further impacting the company's financial outlook.
- Investor Losses: The lack of adequate disclosure regarding the risks associated with the CYPRESS trial has left many investors facing losses, significantly increasing the demand for legal consultation and claims, which may lead to subsequent litigation.
See More
Theravance Biopharma Reports Declining R&D Costs Post CYPRESS Enrollment
- Investor Losses: Following the disclosure of the Phase 3 CYPRESS trial failure on March 3, 2026, Theravance Biopharma shareholders experienced approximately a 26% loss in their investments, indicating significant financial pressure that may affect future fundraising capabilities.
- R&D Spending: The company reported $22 million in operating expenses during the CYPRESS trial enrollment, highlighting substantial cash burn on a single high-risk program, which raises concerns about the company's financial health among investors.
- Cost Decline Claims: Although Theravance framed R&D costs as declining post-enrollment, the actual spending underscores a reliance on a failed trial, potentially impacting future R&D strategies and investor confidence.
- Legal Consultation Information: TBPH investors who suffered losses are encouraged to contact Joseph E. Levi, Esq. for more information, which may lead to potential class action lawsuits, further affecting the company's reputation.
See More
